{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T08:40:31Z","timestamp":1782463231342,"version":"3.54.5"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ctrv.2024.102823","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T23:29:54Z","timestamp":1725406194000},"page":"102823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Precision medicine for multiple myeloma: The case for translocation (11;14)"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0243-4040","authenticated-orcid":false,"given":"Abdul-Hamid","family":"Bazarbachi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Avet-Loiseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Harousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctrv.2024.102823_b0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102823_b0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102823_b0015","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas - current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102823_b0020","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102823_b0025","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","article-title":"Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102823_b0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ijlh.12882","article-title":"Recent advances in cytogenetic characterization of multiple myeloma","volume":"41","author":"Saxe","year":"2019","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102823_b0035","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102823_b0040","first-page":"715","article-title":"Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study","volume":"62","author":"Fonseca","year":"2002","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102823_b0045","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood-2003-02-0493","article-title":"The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma","volume":"102","author":"Fonseca","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102823_b0050","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102823_b0055","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102823_b0060","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1046\/j.1365-2141.1998.00700.x","article-title":"Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases","volume":"101","author":"Fonseca","year":"1998","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102823_b0065","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","article-title":"Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients","volume":"99","author":"Fonseca","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102823_b0070","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood.V98.7.2266","article-title":"Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis","volume":"98","author":"Hayman","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102823_b0075","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","article-title":"Genomic abnormalities in monoclonal gammopathy of undetermined significance","volume":"100","author":"Fonseca","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102823_b0080","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2002-11-3333","article-title":"CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma","volume":"102","author":"Robillard","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102823_b0085","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/sj.leu.2403091","article-title":"t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma","volume":"17","author":"Garand","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2024.102823_b0090","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H, Garand R, Lod\u00e9 L, Harousseau J-L, Bataille Rg, My\u00e9lome ftIFd. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood 2003;101(4):1570-1571. DOI: 10.1182\/blood-2002-08-2436.","DOI":"10.1182\/blood-2002-08-2436"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102823_b0095","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/sonc.2003.50053","article-title":"14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia","volume":"30","author":"Avet-Loiseau","year":"2003","journal-title":"Semin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102823_b0100","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2008.4","article-title":"Genetic aberrations and survival in plasma cell leukemia","volume":"22","author":"Tiedemann","year":"2008","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102823_b0105","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/leu.2016.369","article-title":"Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category","volume":"31","author":"Muchtar","year":"2017","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.ctrv.2024.102823_b0115","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1182\/blood.2021011452","article-title":"IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM","volume":"138","author":"Bazarbachi","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102823_b0120","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.leukres.2013.06.020","article-title":"t(11;14) multiple myeloma: A subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome","volume":"37","author":"An","year":"2013","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102823_b0125","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/leu.2017.204","article-title":"Natural history of t(11;14) multiple myeloma","volume":"32","author":"Lakshman","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102823_b0130","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/leu.2013.258","article-title":"Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma","volume":"28","author":"Greenberg","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102823_b0135","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1182\/blood.V99.6.2185","article-title":"Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation","volume":"99","author":"Avet-Loiseau","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102823_b0140","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1309\/4W8E-8F4K-BHUP-UBE7","article-title":"The (11;14) (q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study","volume":"113","author":"Hoyer","year":"2000","journal-title":"Am J Clin Pathol"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102823_b0145","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1111\/cas.15073","article-title":"Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence","volume":"112","author":"Kitadate","year":"2021","journal-title":"Cancer Sci"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102823_b0150","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1158\/1078-0432.CCR-04-1489","article-title":"Genetic abnormalities and patterns of antigenic expression in multiple myeloma","volume":"11","author":"Mateo","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102823_b0155","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000507414","article-title":"Multiple Myeloma Presenting in Patients Younger than 50 Years of Age: A Single Institution Experience","volume":"144","author":"Duek","year":"2020","journal-title":"Acta Haematol"},{"key":"10.1016\/j.ctrv.2024.102823_b0160","article-title":"Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients. Blood","volume":"9(2):15","author":"Kazandjian","year":"2019","journal-title":"Cancer J"},{"key":"10.1016\/j.ctrv.2024.102823_b0165","doi-asserted-by":"crossref","unstructured":"Baughn LB, Pearce K, Larson D, et al. Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. Blood Cancer J 2018;8(10):96. (In eng). DOI: 10.1038\/s41408-018-0132-1.","DOI":"10.1038\/s41408-018-0132-1"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2024.102823_b0170","doi-asserted-by":"crossref","first-page":"8026","DOI":"10.1182\/blood-2022-166491","article-title":"The Impact of Hispanic Ethnicity on Disease Characteristics in Multiple Myeloma","volume":"140","author":"Cicero","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102823_b0175","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.clml.2021.08.007","article-title":"Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry","volume":"22","author":"Gasparetto","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102823_b0180","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/cncr.33208","article-title":"African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States","volume":"127","author":"Badar","year":"2021","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102823_b0185","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/ng.2583","article-title":"The CCND1 c.870G>A polymorphism is a risk factor for t(11;14) (q13;q32) multiple myeloma","volume":"45","author":"Weinhold","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2024.102823_b0190","doi-asserted-by":"crossref","unstructured":"Solimando AG, Da Vi\u00e0 MC, Cicco S, et al. High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment. J Clin Med 2019;8(7) (In eng). DOI: 10.3390\/jcm8070997.","DOI":"10.3390\/jcm8070997"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102823_b0195","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells","volume":"15","author":"Nutt","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"22","key":"10.1016\/j.ctrv.2024.102823_b0200","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ctrv.2024.102823_b0205","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102823_b0210","doi-asserted-by":"crossref","unstructured":"Sethi S, Epstein-Peterson Z, Kumar A, Ho C. Current Knowledge in Genetics, Molecular Diagnostic Tools, and Treatments for Mantle Cell Lymphomas. Front Oncol 2021;11:739441. (In eng). DOI: 10.3389\/fonc.2021.739441.","DOI":"10.3389\/fonc.2021.739441"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102823_b0215","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood.2020005289","article-title":"Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes","volume":"136","author":"Nadeu","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102823_b0220","first-page":"1437","article-title":"Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster","volume":"7","author":"Williams","year":"1993","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102823_b0225","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/gcc.2870080204","article-title":"Expanded range of 11q13 breakpoints with differing patterns of cyclin D1 expression in B-cell malignancies","volume":"8","author":"Raynaud","year":"1993","journal-title":"Genes Chromosomes Cancer"},{"issue":"14","key":"10.1016\/j.ctrv.2024.102823_b0230","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2012-02-412791","article-title":"IgH partner breakpoint sequences provide evidence that AID initiates t(11;14) and t(8;14) chromosomal breaks in mantle cell and Burkitt lymphomas","volume":"120","author":"Greisman","year":"2012","journal-title":"Blood"},{"issue":"19 Suppl","key":"10.1016\/j.ctrv.2024.102823_b0235","first-page":"5541s","article-title":"Characterization of chromosome 11 translocation breakpoints at the bcl-1 and PRAD1 loci in centrocytic lymphoma","volume":"52","author":"Williams","year":"1992","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.ctrv.2024.102823_b0240","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2012-12-471888","article-title":"Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells","volume":"121","author":"Walker","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102823_b0245","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2141.1992.tb08171.x","article-title":"Comparison of chromosome analysis and BCL-1 rearrangement in a series of patients with multiple myeloma","volume":"81","author":"Fiedler","year":"1992","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102823_b0250","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0165-4608(94)00211-8","article-title":"Molecular breakpoints of t(11;14) (q13;q32) in multiple myeloma","volume":"83","author":"Meeus","year":"1995","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102823_b0255","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1182\/blood.V89.1.349","article-title":"The t(11;14) (q13;q32) in multiple myeloma cell line KMS12 has its 11q13 breakpoint 330 kb centromeric from the cyclin D1 gene","volume":"89","author":"Vaandrager","year":"1997","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102823_b0260","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1182\/blood.V93.4.1330","article-title":"Molecular analysis of 11q13 breakpoints in multiple myeloma","volume":"93","author":"Ronchetti","year":"1999","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102823_b0265","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/gcc.22372","article-title":"Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?","volume":"55","author":"Leiba","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102823_b0270","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1111\/bjh.17627","article-title":"Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma","volume":"195","author":"Bal","year":"2021","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2024.102823_b0275","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2023-184870","article-title":"11q Gain with t(11;14) or Alone Were Associated with Poor Prognosis in Newly-Diagnosed Multiple Myeloma Patients By SNP-Array Analysis and FISH","volume":"142","author":"Lu","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102823_b0280","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102823_b0285","doi-asserted-by":"crossref","unstructured":"Skerget S, Penaherrera D, Chari A, et al. Genomic Basis of Multiple Myeloma Subtypes from the MMRF CoMMpass Study. medRxiv 2021:2021.08.02.21261211. DOI: 10.1101\/2021.08.02.21261211.","DOI":"10.1101\/2021.08.02.21261211"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102823_b0290","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood.2023020276","article-title":"Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency","volume":"143","author":"Leblay","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102823_b0300","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood.V86.11.4250.bloodjournal86114250","article-title":"Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities","volume":"86","author":"Tricot","year":"1995","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102823_b0305","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1200\/JCO.2000.18.4.804","article-title":"Predictive role of interphase cytogenetics for survival of patients with multiple myeloma","volume":"18","author":"Konigsberg","year":"2000","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102823_b0310","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1182\/blood-2002-03-0749","article-title":"Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy","volume":"100","author":"Moreau","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102823_b0315","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2005-05-1981","article-title":"Relationship of patient survival and chromosome anomalies detected in metaphase and\/or interphase cells at diagnosis of myeloma","volume":"106","author":"Dewald","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102823_b0320","doi-asserted-by":"crossref","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106(8):2837-40. (In eng). DOI: 10.1182\/blood-2005-04-1411.","DOI":"10.1182\/blood-2005-04-1411"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102823_b0325","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.leu.2404413","volume":"21","author":"Guti\u00e9rrez","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102823_b0330","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0025-6196(11)61029-X","article-title":"Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement","volume":"82","author":"Dispenzieri","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102823_b0335","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102823_b0340","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/leu.2015.309","article-title":"Clinical value of molecular subtyping multiple myeloma using gene expression profiling","volume":"30","author":"Weinhold","year":"2016","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2024.102823_b0345","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1182\/blood-2023-181783","article-title":"Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma","volume":"142","author":"Kaufman","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102823_b0350","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102823_b0355","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102823_b0360","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102823_b0365","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102823_b0370","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.ctrv.2024.102823_b0375","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102823_b0380","doi-asserted-by":"crossref","first-page":"1061438","DOI":"10.3389\/fonc.2022.1061438","article-title":"CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14)","volume":"12","author":"Jian","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102823_b0385","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/sj.leu.2404558","article-title":"Rituximab in CD20 positive multiple myeloma","volume":"21","author":"Moreau","year":"2007","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102823_b0390","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102823_b0395","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102823_b0400","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.bbmt.2018.11.003","article-title":"Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation","volume":"25","author":"Takamatsu","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"10.1016\/j.ctrv.2024.102823_b0405","doi-asserted-by":"crossref","first-page":"6781","DOI":"10.1158\/1078-0432.CCR-19-0706","article-title":"Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis","volume":"25","author":"Saini","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102823_b0410","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2011-01-327197","article-title":"Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL\/Bcl-2 in Mcl-1-expressing myeloma cells","volume":"118","author":"Morales","year":"2011","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.ctrv.2024.102823_b0415","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1182\/blood-2018-09-876433","article-title":"Variable BCL2\/BCL2L1 ratio in multiple myeloma with t(11;14)","volume":"132","author":"Cleynen","year":"2018","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ctrv.2024.102823_b0420","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ctrv.2024.102823_b0425","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102823_b0430","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2024.102823_b0435","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/bloodadvances.2020004146","article-title":"Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"5","author":"Costa","year":"2021","journal-title":"Blood Adv"},{"issue":"32","key":"10.1016\/j.ctrv.2024.102823_b0440","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1200\/JCO.21.00443","article-title":"Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)","volume":"39","author":"Bahlis","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2024.102823_b0445","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood-2023-180766","article-title":"Venetoclax in Combination with Daratumumab and Dexamethasone Elicits Deep, Durable Responses in Patients with t(11;14) Relapsed\/Refractory Multiple Myeloma: Updated Analyses of Minimal Residual Disease Negativity in Phase 1\/2 Study","volume":"142","author":"Bahlis","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102823_b0450","series-title":"International Myeloma Society 2023 Annual Meeting Abstract OA-52 Presented September 29","article-title":"Results from the randomized, open-label phase 3 CANOVA study of venetoclax-dexamethasone versus pomalidomide-dexamethasone in patients with t(11:14)-positive relapsed\/refractory multiple myeloma","author":"Mateos","year":"2023"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102823_b0455","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/10428194.2021.2010065","article-title":"Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression","volume":"63","author":"Roy","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102823_b0460","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/ejh.12986","article-title":"Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)","volume":"100","author":"Gonsalves","year":"2018","journal-title":"Eur J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2024.102823_b0465","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2023-178735","article-title":"Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed\/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose","volume":"142","author":"Quach","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102823_b0470","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.clml.2022.10.006","article-title":"Cobimetinib Alone and Plus Venetoclax With\/Without Atezolizumab in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"23","author":"Schjesvold","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102823_b0475","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/cam4.4451","article-title":"Filanesib plus bortezomib and dexamethasone in relapsed\/refractory t(11;14) and 1q21 gain multiple myeloma","volume":"11","author":"Pan","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2024.102823_b0480","doi-asserted-by":"crossref","unstructured":"Wong KY, Chim CS. Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma. J Pharm Pharmacol 2020;72(5):728-737. (In eng). DOI: 10.1111\/jphp.13240.","DOI":"10.1111\/jphp.13240"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102823_b0485","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/j.clml.2019.09.081","article-title":"A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma","volume":"19","author":"Spencer","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102823_b0490","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.3324\/haematol.2018.212308","article-title":"Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma","volume":"105","author":"Algar\u00edn","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102823_b0495","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41419-020-2505-1","article-title":"Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX\/BAK hetero-complexes","volume":"11","author":"Seiller","year":"2020","journal-title":"Cell Death Dis"},{"issue":"18","key":"10.1016\/j.ctrv.2024.102823_b0500","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.2019003633","article-title":"Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria","volume":"135","author":"Kimmich","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102823_b0505","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-020-00397-w","article-title":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis","volume":"11","author":"Premkumar","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ctrv.2024.102823_b0510","doi-asserted-by":"crossref","unstructured":"Sidiqi MH, Al Saleh AS, Leung N, et al. Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer J 2020;10(5):55. (In eng). DOI: 10.1038\/s41408-020-0321-6.","DOI":"10.1038\/s41408-020-0321-6"},{"key":"10.1016\/j.ctrv.2024.102823_b0515","doi-asserted-by":"crossref","unstructured":"Bazarbachi AH, Bhutani D, Radhakrishnan J, et al. Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosis. Am J Hematol 2024 (In eng). DOI: 10.1002\/ajh.27450.","DOI":"10.1016\/S2152-2650(24)00948-0"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102823_b0520","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjh.18243","article-title":"How do we manage t(11;14) plasma cell disorders with venetoclax?","volume":"199","author":"Chakraborty","year":"2022","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102823_b0525","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.clml.2021.07.029","article-title":"A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed\/Refractory Multiple Myeloma","volume":"21","author":"Gasparetto","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102823_b0530","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ajh.26083","article-title":"Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma","volume":"96","author":"Kaufman","year":"2021","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102823_b0535","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/jcph.858","article-title":"Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model","volume":"57","author":"Freise","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102823_b0540","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40261-016-0485-9","article-title":"Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers","volume":"37","author":"Salem","year":"2017","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ctrv.2024.102823_b0545","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127593","article-title":"Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients","author":"Neri","year":"20191341572","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.ctrv.2024.102823_b0550","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/blood.2020007899","article-title":"Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression","volume":"137","author":"Gupta","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102823_b0555","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1038\/sj.leu.2403090","article-title":"Many and multiple myeloma(s)","volume":"17","author":"Fonseca","year":"2003","journal-title":"Leukemia"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T18:20:07Z","timestamp":1729016407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224001518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":109,"alternative-id":["S0305737224001518"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102823","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision medicine for multiple myeloma: The case for translocation (11;14)","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102823","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102823"}}